Silpa Narayanan

698 total citations
18 papers, 518 citations indexed

About

Silpa Narayanan is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Silpa Narayanan has authored 18 papers receiving a total of 518 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Silpa Narayanan's work include Drug Transport and Resistance Mechanisms (9 papers), Cancer therapeutics and mechanisms (7 papers) and Synthesis and biological activity (4 papers). Silpa Narayanan is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Cancer therapeutics and mechanisms (7 papers) and Synthesis and biological activity (4 papers). Silpa Narayanan collaborates with scholars based in United States, China and Pakistan. Silpa Narayanan's co-authors include Zhe‐Sheng Chen, Chao‐Yun Cai, Qingbin Cui, Charles R. Ashby, Juanjuan Huang, Liuya Wei, Yehuda G. Assaraf, Huiqin Guo, Pranav Gupta and Pengli Bu and has published in prestigious journals such as Cancer Research, International Journal of Molecular Sciences and Cancer Letters.

In The Last Decade

Silpa Narayanan

18 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Silpa Narayanan United States 10 304 193 67 63 54 18 518
Tohru Obata Japan 16 320 1.1× 180 0.9× 52 0.8× 144 2.3× 24 0.4× 48 755
Julia Mantaj United Kingdom 11 245 0.8× 135 0.7× 76 1.1× 114 1.8× 58 1.1× 19 498
Emma S. Child United Kingdom 10 354 1.2× 235 1.2× 55 0.8× 66 1.0× 23 0.4× 16 560
María José Guillén Spain 11 164 0.5× 96 0.5× 48 0.7× 55 0.9× 18 0.3× 45 385
Mário Šereš Slovakia 13 337 1.1× 261 1.4× 77 1.1× 38 0.6× 11 0.2× 26 536
Du‐Shieng Chien United States 15 314 1.0× 148 0.8× 68 1.0× 48 0.8× 172 3.2× 22 783
Marit Liland Sandvold Netherlands 15 462 1.5× 222 1.2× 76 1.1× 68 1.1× 24 0.4× 27 725
D Mingying China 3 377 1.2× 330 1.7× 107 1.6× 25 0.4× 12 0.2× 5 681
Matthijs J. van Haren Netherlands 19 506 1.7× 147 0.8× 41 0.6× 100 1.6× 11 0.2× 31 856
Qie Guo China 13 209 0.7× 100 0.5× 77 1.1× 49 0.8× 12 0.2× 41 497

Countries citing papers authored by Silpa Narayanan

Since Specialization
Citations

This map shows the geographic impact of Silpa Narayanan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silpa Narayanan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silpa Narayanan more than expected).

Fields of papers citing papers by Silpa Narayanan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silpa Narayanan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silpa Narayanan. The network helps show where Silpa Narayanan may publish in the future.

Co-authorship network of co-authors of Silpa Narayanan

This figure shows the co-authorship network connecting the top 25 collaborators of Silpa Narayanan. A scholar is included among the top collaborators of Silpa Narayanan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silpa Narayanan. Silpa Narayanan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Narayanan, Silpa, Qiu‐Xu Teng, Zhuo‐Xun Wu, et al.. (2022). Anticancer effect of Indanone-based thiazolyl hydrazone derivative on p53 mutant colorectal cancer cell lines: An in vitro and in vivo study. Frontiers in Oncology. 12. 949868–949868. 6 indexed citations
2.
Wu, Zhuo‐Xun, Yuqi Yang, Zi‐Ning Lei, et al.. (2022). ABCB1 limits the cytotoxic activity of TAK-243, an inhibitor of the ubiquitin-activating enzyme UBA1. Frontiers in Bioscience-Landmark. 27(1). 5–5. 5 indexed citations
3.
Narayanan, Silpa, Jing‐Quan Wang, Zhuo‐Xun Wu, et al.. (2021). The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter. International Journal of Molecular Sciences. 22(5). 2463–2463. 13 indexed citations
4.
Narayanan, Silpa, Yingfang Fan, Qiu‐Xu Teng, et al.. (2021). VKNG-1 Antagonizes ABCG2-Mediated Multidrug Resistance via p-AKT and Bcl-2 Pathway in Colon Cancer: In Vitro and In Vivo Study. Cancers. 13(18). 4675–4675. 8 indexed citations
5.
Wu, Zhuo‐Xun, Yuqi Yang, Jing‐Quan Wang, et al.. (2021). Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Frontiers in Cell and Developmental Biology. 9. 697927–697927. 11 indexed citations
6.
Lei, Zi‐Ning, Qiu‐Xu Teng, Pranav Gupta, et al.. (2021). Cabozantinib Reverses Topotecan Resistance in Human Non-Small Cell Lung Cancer NCI-H460/TPT10 Cell Line and Tumor Xenograft Model. Frontiers in Cell and Developmental Biology. 9. 640957–640957. 12 indexed citations
7.
Narayanan, Silpa, Zhuo‐Xun Wu, Jing‐Quan Wang, et al.. (2021). The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. International Journal of Biological Sciences. 17(10). 2652–2665. 6 indexed citations
8.
Narayanan, Silpa, et al.. (2021). Synthesis, Characterization and Cytotoxic Effect of Some New Thiazolyl Hydrazone Derivatives of 1-Indanone. Journal of the chemical society of pakistan. 43(2). 244–244. 2 indexed citations
9.
Narayanan, Silpa, Qiu‐Xu Teng, Jing‐Quan Wang, et al.. (2020). Abstract 3010: VKNG 1 reverses multidrug resistance by inhibiting ABCG2 mediated drug transport in vitro and in vivo. Cancer Research. 80(16_Supplement). 3010–3010. 3 indexed citations
10.
Narayanan, Silpa, et al.. (2020). Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates. Journal of Natural Products. 83(5). 1563–1570. 9 indexed citations
11.
Narayanan, Silpa, et al.. (2019). Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. The International Journal of Biochemistry & Cell Biology. 110. 21–28. 40 indexed citations
12.
Narayanan, Silpa, Chao‐Yun Cai, Yehuda G. Assaraf, et al.. (2019). Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resistance Updates. 48. 100663–100663. 252 indexed citations
13.
Gupta, Pranav, Zi‐Ning Lei, Dan Liao, et al.. (2018). Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters. 442. 91–103. 49 indexed citations
14.
Gupta, Pranav, Silpa Narayanan, Yi‐Jun Wang, et al.. (2017). GSK1904529A, a Potent IGF‐IR Inhibitor, Reverses MRP1‐Mediated Multidrug Resistance. Journal of Cellular Biochemistry. 118(10). 3260–3267. 19 indexed citations
15.
Bu, Pengli, et al.. (2016). Cytotoxicity assessment of lipid-based self-emulsifying drug delivery system with Caco-2 cell model: Cremophor EL as the surfactant. European Journal of Pharmaceutical Sciences. 91. 162–171. 46 indexed citations
16.
17.
Narayanan, Silpa. (2014). COMPARATIVE STUDY ON EFFECT OF ALUMINIUM CHLORIDE AND ALUMINIUM HYDROXIDE ON SERUM BIOCHEMICAL PARAMETERS IN WISTAR ALBINO RATS. International Journal of Pharma and Bio Sciences. 2 indexed citations
18.
Narayanan, Silpa, et al.. (2002). Permeation Of Diclofenac Through Buccal Mucosa. Indian Journal of Pharmaceutical Sciences. 64(4). 373–377. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tohru Obata Breakdown of academic impact, for papers by Julia Mantaj Breakdown of academic impact, for papers by Emma S. Child Breakdown of academic impact, for papers by María José Guillén Breakdown of academic impact, for papers by Mário Šereš Breakdown of academic impact, for papers by Du‐Shieng Chien Breakdown of academic impact, for papers by Marit Liland Sandvold Breakdown of academic impact, for papers by D Mingying Breakdown of academic impact, for papers by Matthijs J. van Haren Breakdown of academic impact, for papers by Qie Guo
Rankless by CCL
2026